Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that new clinical data from a second Phase I study of its lead programme, IMCgp100, will be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 3 June 2017.